Predicting Pharmacodynamic Effects Through Early Drug Discovery with Artificial Intelligence-physiologically Based Pharmacokinetic (AI-PBPK) Modelling

Overview

Journal Front Pharmacol

Date 2024 Mar 4

PMID 38434709

Authors

Keheng Wu

Xue Li

Zhou Zhou

Youni Zhao

Mei Su

Zhuo Cheng

Xinyi Wu

Zhijun Huang

Xiong Jin

Jingxi Li

Mengjun Zhang

Jack Liu

Bo Liu

Affiliations

Soon will be listed here.

Abstract

A mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model links the concentration-time profile of a drug with its therapeutic effects based on the underlying biological or physiological processes. Clinical endpoints play a pivotal role in drug development. Despite the substantial time and effort invested in screening drugs for favourable pharmacokinetic (PK) properties, they may not consistently yield optimal clinical outcomes. Furthermore, in the virtual compound screening phase, researchers cannot observe clinical outcomes in humans directly. These uncertainties prolong the process of drug development. As incorporation of Artificial Intelligence (AI) into the physiologically based pharmacokinetic/pharmacodynamic (PBPK) model can assist in forecasting pharmacodynamic (PD) effects within the human body, we introduce a methodology for utilizing the AI-PBPK platform to predict the PK and PD outcomes of target compounds in the early drug discovery stage. In this integrated platform, machine learning is used to predict the parameters for the model, and the mechanism-based PD model is used to predict the PD outcome through the PK results. This platform enables researchers to align the PK profile of a drug with desired PD effects at the early drug discovery stage. Case studies are presented to assess and compare five potassium-competitive acid blocker (P-CAB) compounds, after calibration and verification using vonoprazan and revaprazan.

Citing Articles

Risks of anti- therapy and long-term therapy with antisecretory drugs.

Kotelevets S World J Gastroenterol. 2025; 31(4):101933.

PMID: 39877710 PMC: 11718649. DOI: 10.3748/wjg.v31.i4.101933.

Computational identification of novel natural inhibitors against triple mutant DNA gyrase A in fluoroquinolone-resistant Typhimurium.

Haryini S, C G Biochem Biophys Rep. 2025; 41:101901.

PMID: 39867681 PMC: 11764029. DOI: 10.1016/j.bbrep.2024.101901.

References

Mulford D, Leifke E, Hibberd M, Howden C . The Effect of Food on the Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan. Clin Pharmacol Drug Dev. 2021; 11(2):278-284. PMC: 9291755. DOI: 10.1002/cpdd.1009. View

Kondo M, Kawamoto M, Hasuoka A, Kajino M, Inatomi N, Tarui N . High-throughput screening of potassium-competitive acid blockers. J Biomol Screen. 2011; 17(2):177-82. DOI: 10.1177/1087057111421004. View

Kim H, Park S, Cheung D, Cho Y, Kim J, Kim S . Clinical trial: inhibitory effect of revaprazan on gastric acid secretion in healthy male subjects. J Gastroenterol Hepatol. 2010; 25(10):1618-25. DOI: 10.1111/j.1440-1746.2010.06408.x. View

Tack J, Vladimirov B, Horny I, Chong C, Eisner J, Czerniak R . Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a.... Neurogastroenterol Motil. 2022; 35(1):e14468. DOI: 10.1111/nmo.14468. View

Jimenez-Luna J, Skalic M, Weskamp N, Schneider G . Coloring Molecules with Explainable Artificial Intelligence for Preclinical Relevance Assessment. J Chem Inf Model. 2021; 61(3):1083-1094. DOI: 10.1021/acs.jcim.0c01344. View

Suzuki T, Kagami T, Uotani T, Yamade M, Hamaya Y, Iwaizumi M . Comparison of effect of an increased dosage of vonoprazan versus vonoprazan plus lafutidine on gastric acid inhibition and serum gastrin. Eur J Clin Pharmacol. 2017; 74(1):45-52. DOI: 10.1007/s00228-017-2324-1. View

Li C, Su M, Yan Y, Zhou L, Ao L, Fang W . KFP-H008 blocks gastric acid secretion through inhibiting H-K-ATPase. Eur J Pharmacol. 2017; 810:112-119. DOI: 10.1016/j.ejphar.2017.06.020. View

Zhang J, Wu K, Liu B, Hou S, Li X, Ye X . Bioequivalence study of ipratropium bromide inhalation aerosol using PBPK modelling. Front Med (Lausanne). 2023; 10:1056318. PMC: 9941642. DOI: 10.3389/fmed.2023.1056318. View

Luo H, Deng W, Zou K . Protonated form: the potent form of potassium-competitive acid blockers. PLoS One. 2014; 9(5):e97688. PMC: 4028304. DOI: 10.1371/journal.pone.0097688. View

10.

Zhang F, Zhou Y, Wu N, Jia R, Liu A, Liu B . In silico prediction of bioequivalence of Isosorbide Mononitrate tablets with different dissolution profiles using PBPK modeling and simulation. Eur J Pharm Sci. 2020; 157:105618. DOI: 10.1016/j.ejps.2020.105618. View

11.

Hori Y, Imanishi A, Matsukawa J, Tsukimi Y, Nishida H, Arikawa Y . 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases. J Pharmacol Exp Ther. 2010; 335(1):231-8. DOI: 10.1124/jpet.110.170274. View

12.

Ropp P, Kaminsky J, Yablonski S, Durrant J . Dimorphite-DL: an open-source program for enumerating the ionization states of drug-like small molecules. J Cheminform. 2019; 11(1):14. PMC: 6689865. DOI: 10.1186/s13321-019-0336-9. View

13.

Jia R, Zhang F, Wu N, Xu W, Gao H, Liu B . Accelerating Development of Benziamidazole-Class Proton Pump Inhibitors: A Mechanism-Based PK/PD Model to Optimize Study Design with Ilaprazole as a Case Drug. Pharmaceutics. 2021; 13(3). PMC: 7998456. DOI: 10.3390/pharmaceutics13030392. View

14.

Sakurai Y, Mori Y, Okamoto H, Nishimura A, Komura E, Araki T . Acid-inhibitory effects of vonoprazan 20 mg compared with esomeprazole 20 mg or rabeprazole 10 mg in healthy adult male subjects--a randomised open-label cross-over study. Aliment Pharmacol Ther. 2015; 42(6):719-30. DOI: 10.1111/apt.13325. View

15.

Chen E, Bondi R, Michalski P . Model-based Target Pharmacology Assessment (mTPA): An Approach Using PBPK/PD Modeling and Machine Learning to Design Medicinal Chemistry and DMPK Strategies in Early Drug Discovery. J Med Chem. 2021; 64(6):3185-3196. DOI: 10.1021/acs.jmedchem.0c02033. View

16.

Jenkins H, Sakurai Y, Nishimura A, Okamoto H, Hibberd M, Jenkins R . Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects. Aliment Pharmacol Ther. 2015; 41(7):636-48. PMC: 4654261. DOI: 10.1111/apt.13121. View

17.

Jenkins H, Jenkins R, Patat A . Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study. Clin Drug Investig. 2016; 37(3):311-316. DOI: 10.1007/s40261-016-0488-6. View

18.

Freitas A, Limbu K, Ghafourian T . Predicting volume of distribution with decision tree-based regression methods using predicted tissue:plasma partition coefficients. J Cheminform. 2015; 7:6. PMC: 4356883. DOI: 10.1186/s13321-015-0054-x. View

19.

Kong W, Sun B, Wang Z, Zheng X, Zhao K, Chen Y . Physiologically based pharmacokinetic-pharmacodynamic modeling for prediction of vonoprazan pharmacokinetics and its inhibition on gastric acid secretion following intravenous/oral administration to rats, dogs and humans. Acta Pharmacol Sin. 2020; 41(6):852-865. PMC: 7468366. DOI: 10.1038/s41401-019-0353-2. View

20.

Wendling T, Dumitras S, Ogungbenro K, Aarons L . Application of a Bayesian approach to physiological modelling of mavoglurant population pharmacokinetics. J Pharmacokinet Pharmacodyn. 2015; 42(6):639-57. DOI: 10.1007/s10928-015-9430-4. View